Basit öğe kaydını göster

dc.contributor.authorGuler, Omer Faruk
dc.contributor.authorTonyali, Senol
dc.contributor.authorKaraaslan, Mustafa
dc.contributor.authorToprak, Tuncay
dc.contributor.authorBicer, Sait
dc.contributor.authorYilmaz, Mehmet
dc.contributor.authorOdabas, Oner
dc.date.accessioned2021-12-10T11:48:17Z
dc.date.available2021-12-10T11:48:17Z
dc.identifier.citationYilmaz M., Odabas O., Karaaslan M., Guler O. F. , Toprak T., Bicer S., Tonyali S., "Predicting risk of erectile dysfunction in patients with nonalcoholic fatty liver disease", ANDROLOGIA, 2021
dc.identifier.issn0303-4569
dc.identifier.othervv_1032021
dc.identifier.otherav_95f64425-1783-44d2-a640-63afa97556f3
dc.identifier.urihttp://hdl.handle.net/20.500.12627/172667
dc.identifier.urihttps://doi.org/10.1111/and.14091
dc.description.abstractNonalcoholic fatty liver disease (NAFLD) is one of the risk factors for erectile dysfunction (ED). We aimed to predict the risk of ED in patients with NAFLD. The study included 146 male patients complaining impotence admitted to the urology outpatient clinic aged 24-80 years without a history of alcohol use who underwent abdominal ultrasonography between February 2018 and January 2019. 106 patients with NAFLD and 40 men without NAFLD were included in the study. Clinical and laboratory parameters, ED status according to International Index of Erectile Function-5 were compared between patients with and without NAFLD. The mean age of patients was 51.47 +/- 10.34 years. NAFLD was detected in 72.6% of the patients. No statistically significant difference was found regarding mean age, BMI, IIEF-5 scores, DM status, serum glucose levels (p > .05). Fasting insulin levels, hypertension (HT), insulin resistance (IR) and ED status of the patients with NAFLD were significantly higher than patients without NAFLD (p < .05). NAFLD was found to be a significantly independent associated with ED. We also found that patients with NAFLD have risk of ED 2.92 times higher than without NAFLD (OR: 2.92). For the patients presenting with erectile dysfunction, hepatic steatosis should also be considered.
dc.language.isoeng
dc.subjectİç Hastalıkları
dc.subjectEndokrinoloji ve Metabolizma Hastalıkları
dc.subjectEndocrinology
dc.subjectEndocrine and Autonomic Systems
dc.subjectEndocrinology, Diabetes and Metabolism
dc.subjectReproductive Medicine
dc.subjectLife Sciences
dc.subjectHealth Sciences
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectTıp
dc.subjectENDOKRİNOLOJİ VE METABOLİZMA
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectANDROLOJİ
dc.titlePredicting risk of erectile dysfunction in patients with nonalcoholic fatty liver disease
dc.typeMakale
dc.relation.journalANDROLOGIA
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.contributor.firstauthorID2634647


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster